<div id="readability-page-1"><p>Roth MKM analyst Boobalan Pachaiyappan maintained a Buy rating on PolyPid today and set a price target of $9.00.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Pachaiyappan is a 4-star analyst with an average return of <span>20.3%</span> and a 49.11% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Capricor Therapeutics, PolyPid, and CervoMed.</p> <p>PolyPid has an analyst consensus of Strong Buy, with a price target consensus of $11.00.</p></div>

PYPD

<p>Roth MKM analyst Boobalan Pachaiyappan maintains a Buy rating on PolyPid, setting a price target of $9.00. Pachaiyappan, a 4-star analyst with a 20.3% average return, covers the Healthcare sector. PolyPid has a Strong Buy consensus with a price target of $11.00.</p>

PolyPid (PYPD) Receives a Buy from Roth MKM